S&P Highlights Biotech ETFs

Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple sclerosis, biotechnology stocks and ETFs have been stellar performers in 2013. Recently, it was an announcement by Vertex (NASDAQ: VRTX ) that its cystic fibrosis